Daily low dose intravesical cidofovir for the treatment of BK virus associated hemorrhagic cystitis after allogeneic stem cell transplantation

Introduction: BK virus associated hemorrhagic cystitis(BKV-AHC) is a serious complication observed after allo-geneic stem cell transplantation and the current therapeutic options are scarce with substantial renal side effects. Although the guidelines recommend intravenous cidofovir application with caution to nephrotoxicity, there are few studies which investigated intravesical administration and reported similar therapeutic results with less renal side effects. Methods: We administered low dose, daily and consecutive (75 mg/day, for 5 days) intravesical cidofovir to 25 patients with BKV-AHC that developed after (ASCT). Results: The response rate in our cohort was 92% and relapse was not encountered in 84% of the patient population during one year of follow-up. The median BK urine viral load significantly decreased from 260,000,000 IU/mL to 53,000,000 IU/mL after a week of treatment (p = 0.0001). Rise in serum creatinine was observed in 5 patients during treatment and post-treatment nephrotoxicity was seen in only 1 patient. Conclusions: Daily low dose intravesical cidofovir might be an effective treatment option for BKV-AHC after ASCT with favorable less systemic side effects.

Automated summary

This study investigated the efficacy of low dose daily consecutive intravesical cidofovir in 25 patients with BK virus associated hemorrhagic cystitis after allo-geneic stem cell transplantation. The overall response rate was 92% and relapse was not observed in 84% of patients during one year of follow-up. The median BK urine viral load significantly decreased after one week of treatment. Only 1 patient experienced post-treatment nephrotoxicity.